Sealonix Inc.
$186.9K 19 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Reichert, Inc.
Reichert, Inc. reported $186,784.61 across General Payments, Research, and Ownership to 75 physicians and teaching hospitals across 75 transactions.
- $186.8K Below-median payer
- All-tracks total
- 75 Below-median volume
- Transactions
- 75 Below-median reach
- Recipients
- +$85.0K
- General Payments vs PY2023
Reichert, Inc. reported $186,784.61 across all CMS Open Payments tracks (General + Research + Ownership) to 75 physicians and teaching hospitals in Program Year 2024 - ranking #1023 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $186,784.61, averaging $2.5K per recipient.
Reichert, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
14/100
Total payments
F
12/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer reichert-inc Reichert, Inc.
$186.8K · #1023/1,925 · 0.0% industry · PY2024
- TOT $186.8K
- RANK #1023
- SHARE 0.0%
- TXN 75
- RCP 75
- CAT 2
- GEN $186.8K
- ΔGEN +$85.0K
- TOP1 36.3%
- PY 2024
Volume peers
Nearest volume peer: Sealonix Inc. ($186.9K)
Reichert, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Reichert, Inc.'s CMS-reported General Payments increased by $85.0K (+83.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: REICHERT, INC.PY2023: REICHERT, INC.PY2024: Reichert, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $101,816.35
- PY2024
- $186,784.61
What the Data Shows for Reichert, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Reichert, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Consulting Fee" leads the 2-category general-payment breakdown below at $184.8K (98.9% of General Payments, 74 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Reichert, Inc. made 2 types of general payments. "Consulting Fee" is the largest category at $184.8K, 98.9% of General Payments.
How Reichert, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $184.8K | 74 | 98.9% |
| Compensation for Services Other Than Consulting | $2.0K | 1 | 1.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $142,839.00 (76.5%) of $186,784.61 in this company's General Payments records across 11 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Reichert, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
April Lov Jasper DR
$67,840.00 across 16 reported transactions
- 2
Lisa Marie Genovese DR
$27,999.00 across 1 reported transactions
- 3
Felipe A Medeiros DR
$18,000.00 across 12 reported transactions
- 4
Justin A Schweitzer DR
$16,500.00 across 13 reported transactions
- 5
Inder Paul Singh DR
$12,500.00 across 9 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Reichert, Inc.'s spend rank (#1023 of 1,925, bottom 47% by spend) and concentration rank (#772 of 1,838, top 42% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- NeuroOne Medical Technologies Corporation : $44.7K total payments, HHI 1889
- Eminent Spine, LLC : $35.3K total payments, HHI 1889
- SiVantage, Inc. : $3.8K total payments, HHI 1887
- Air Techniques, Inc. : $23.7K total payments, HHI 1886
- OnMark, Inc. : $93.7K total payments, HHI 1884
- Sechrist Industries Inc : $740.50 total payments, HHI 1882
- Reichert, Inc. (this company) : $186.8K total payments, HHI 1880
- Canary Medical USA LLC : $754.5K total payments, HHI 1873
- Avyxa Pharma, LLC : $17.2K total payments, HHI 1863
- Amarin Pharma Inc. : $199.3K total payments, HHI 1855
- HydroCision, Inc. : $117.1K total payments, HHI 1854
- C. R. Bard, Inc. & Subsidiaries : $865.6K total payments, HHI 1853
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Reichert, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Reichert, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Reichert, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Fisher Scientific Company L.L.C.
$186.1K 299 recipients
Compare payment profiles
VEO Ophthalmics
$185.8K 0 recipients
Compare payment profiles
Kulzer, LLC
$187.8K 1,403 recipients
Compare payment profiles
Maquet Cardiovascular L.L.C.
$188.3K 167 recipients
Compare payment profiles
New York Blood Center, Inc.
$184.6K 74 recipients
Compare payment profiles
Put this to use
Reichert, Inc. ranks #1023 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Reichert, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.